1. Medtech Insight
  2. >>Device Area

ATTD 2021: Despite High Upfront Cost, Medtronic’s 780G Could Offer Cost Savings

 
• By Barnaby Pickering

In a talk at the 2021 Advanced Technologies & Treatments for Diabetes conference, Medtronic's European director of medical affairs explained how its MiniMed 780G insulin pump can reduce long-term treatment costs for diabetics.

Medtronic's MiniMed 780G • Source: Medtronic

Medtronic is touting the cost-effectiveness of its 780G insulin pump as it is counting on the hybrid closed-loop system help restore growth to its diabetes division. 

Ohad Cohen, Medtronic’s director of medical affairs for Europe, the Middle East and Africa, gave a talk during the online 2021 Advanced Technologies & Treatments for Diabetes (ATTD) conference about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.